INTRODUCTION
Chronic obstructive pulmonary disease (COPD) is a slow, progressive disease characterised by poorly reversible airflow limitation. The prevalence of COPD in Spain currently extends to 10.2% of the adult population, reaching 35% in males aged >70 years. 1 In spite of its prevalence, this condition is highly underdiagnosed. 1 In addition, misdiagnosis between COPD and other lung diseases, especially asthma, appears to be an important clinical problem. 2 In most countries, most patients with chronic respiratory diseases are managed by primary care physicians. In the last few years, clinical guidelines, such as the Global initiative for chronic Obstructive Lung Disease (GOLD) 3 and the Global Initiative For Asthma 4 have been developed for the management of COPD and asthma respectively. However, guidelines have been difficult to implement in Spain, particularly in the primary care setting; 5 perhaps because there is a greater focus on secondary than on primary care and these respiratory conditions are perceived as complex, or because some patients in primary care may present with undifferentiated symptoms. 6 Most respiratory guidelines agree that spirometry should be the basis for the diagnosis of COPD, 3, 6, 7 and differential diagnosis of asthma and COPD is based on a combination of history, physical examination, and confirmation of the presence of airflow obstruction (defined as post-bronchodilator forced expiratory volume in 1 second/forced vital capacity [FEV1/FVC] <0.7) using spirometry. In the primary care setting, access to spirometry is often limited by time constraints and difficulty in interpretation, leading to underuse. [8] [9] [10] Symptom-based questionnaires could be used to help differentiate between COPD and asthma among individuals thought to have obstructive lung disease. Used in conjunction with spirometry, these tools may enhance the diagnostic accuracy of obstructive lung disease. 2, 11 Differentiating between asthma and COPD is essential for determining appropriate drug therapy. For the treatment of asthma, inhaled corticosteroids (ICs) are the most effective controller medications currently available. 4 On the other hand, the basis for treatment in COPD is an inhaled (long-acting) bronchodilator, while ICs are usually recommended in patients with severe disease (FEV1 <50%) and in those with a history of recurrent exacerbations. 3, 6, 7 Apart from the poor response to ICs in COPD, the risk of inappropriate use should also be considered. IC therapy has adverse effects, including dysphonia, skin bruising, oral candidiasis, and diminished bone density. In addition, recent studies have demonstrated a higher risk of pneumonia associated with the use of ICs in patients with COPD. 12, 13 In this context, a recent
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Chronic obstructive pulmonary disease (COPD) and asthma treatment must be based on appropriate diagnosis. However, patients receiving inhaled therapy in primary care may not be accurately diagnosed according to current guidelines.
Aim
To analyse the characteristics of patients treated with inhaled medication, the concordance of tools for differential diagnosis, and the adequacy of prescription of inhaled corticosteroids (ICs) in primary care.
Design and setting
Cross-sectional, multicentre, non-interventional study conducted in 10 primary care centres in Barcelona, Spain.
Method
Patients with chronic respiratory disease, aged >40 years were treated with ICs. They provided sociodemographic and clinical information and performed forced spirometry with a bronchodilator test (BDT). The diagnostic accuracy of asthma and COPD diagnoses were tested using two differential diagnosis questionnaires. meta-analysis 14 concluded that the use of ICs in patients with stable COPD does not reduce mortality and significantly increases the incidence of pneumonia. Conversely, the use of long-acting beta agonists (LABAs) as monotherapy for asthma is not recommended for safety reasons.
Results
Taking all of this into account, it is important to increase the awareness of differences between the two diseases to promote optimal treatment. However, most patients receiving inhaled therapy in primary care are not accurately diagnosed according to current guidelines for COPD and asthma. 2, 15 The aim of this study was to analyse the characteristics of patients treated with inhaled medication in primary care, to investigate the concordance of different tools that can be used for the differential diagnosis of COPD and asthma, and to ascertain the adequacy of IC prescription in this population. 20 which establishes five degrees of perceived respiratory disability, ranging from troubled by breathlessness only on strenuous exercise (grade 1) to too breathless to leave the house, or breathless when dressing or undressing (grade 5).
METHOD
Four different diagnostic classifications between asthma and COPD were established:
• Clinical diagnosis. Physicians classified patients as having COPD, asthma, or indeterminate, according to medical history, clinical examination, and their interpretation of spirometry.
• Classification using the Tinkelman et al questionnaire for differentiating COPD and asthma.
• Classification according to the Beeh et al questionnaire for the differentiation of asthma and COPD.
• Classification according to clinical history and spirometry with bronchodilator test as described by Price et al 21 (Table 1) .
Statistical methodology
Sample size was predetermined to be 340 patients, assuming an expected prevalence of COPD of 33% among patients aged >40 years, with inhaled medication, attending primary care centres, by using the normal distribution for large samples with a confidence level of 95% and a two-tail comparison test to estimate the prevalence of patients with a proper diagnosis of COPD with an error of precision <5%. For the main objective, a descriptive analysis of frequencies was employed by means of a prevalence estimate and the corresponding 95% confidence intervals (CIs). Quantitative variables were compared between groups using analysis of variance and the qualitative variables using the χ 2 test. To assess the correlation between the different criteria and methods of diagnosis the power of concordance was determined using the Cohen's Kappa index, considering the following levels of concordance: <0.20 = very low; 0.21 to 0.40 = low; 0.41 to 0.60 = moderate; 0.61 to 0.80 = good and 0.81 to 1 = very good. SPSS (version 16.0) was used for statistical analysis.
How this fits in

RESULTS
Patients characteristics
A total of 29 primary care physicians included 328 patients, four of whom did not fulfil the inclusion and exclusion criteria and were excluded. From the clinical diagnosis based on physicians' criteria, participants were classified into three groups: COPD (64.8%), asthma (15.4%), and indeterminate (19.8%). Their characteristics are shown in Table 2 . Mean FEV1 (% predicted) was 66.7% (standard deviation [SD] = 22.4%) and the mean reversibility was 8.4%, with 49 (18.6%) patients having a positive bronchodilator test. Up to 39.8% of the patients had a post-bronchodilator FEV1/FVC ratio above 0.7, and 40% had moderate-severe airflow obstruction according to the GOLD severity classification. Mean (SD) Charlson Index was 2.1 (SD = 1.5).
Patients diagnosed with asthma according to physicians' criteria had significantly fewer comorbidities (χ 2 test P<0.05). The EuroQoL-5D questionnaire showed significant differences between the three groups in terms of mobility, self-care, and pain. However, EuroQoL-5D visual analogue scale results showed no statistically significant differences. Most of the patients had dyspnoea grades 2 (45%) and 3 (25%), with significant differences in the degree of disability between the three groups. As per protocol requirement, all participants were receiving inhaled medication: 230 (71%) were on treatment with any kind of ICs, of these 150 (65.2%) received a fixed combination with LABAs (Table 2) .
Diagnostic accuracy
A total of 182 (59.3%) patients fulfilled the GOLD criteria for COPD (postbronchodilator FEV1/FVC <0.7). As a result of post-bronchodilator spirometry, patients were placed into one of five mutually exclusive diagnostic categories (Table 1) ; the most frequent was COPD without reversible component (49.6%) and up to 9.8% were classified as probably normal (Table 3 ). The two differential diagnosis questionnaires provided similar percentages of patients with probable COPD (62.8% with the Tinkelman et al and 58.4% with the Beeh et al questionnaire). However, the Beeh et al questionnaire classified 41.6% of patients as probable asthma, whereas the Tinkelman et al questionnaire, focused on COPD, classified 22.4% as indeterminate probability of COPD, and 14.8% as reduced probability of COPD (Table 3) .
The analysis of concordance showed different levels of concordance between the diagnostic methods (Table 4) : concordance was moderate between the clinical diagnosis and spirometry and between the two questionnaires; it was low between the physicians' criteria and the two questionnaires and very low in the other two comparisons: spirometry versus the Tinkelman et al questionnaire and spirometry versus the Beeh et al questionnaire. Global concordance between diagnosis is shown in Table 5 .
Use of inhaled corticosteroids
The use of inhaled medication by clinical diagnosis is shown in On comparing the use of ICs with the patient characteristics, no significant differences were found between IC consumers and non-consumers in terms of age, sex, age at onset, comorbidity, or quality of life. Educational level appeared to have some influence on use of ICs as the percentage of patient not receiving ICs was higher in high school and university patients compared with patients with a lower educational level. Patients treated with ICs were more severe, both in terms of FEV1 (% predicted) and EuroQoL-5D scores (P<0.05 for both comparisons).
Regarding smoking history, there were more active smokers in the non-ICs group (34.1%) than in the ICs group (20.5%; P<0.05; Table 6 ). this study compared different diagnostic methods based on clinical history (including smoking habits), symptoms, and spirometry, knowing that none of these data can be separately considered as definitive. When evaluating the agreement in the diagnosis reached by each method, this study found a moderate concordance between the clinical and spirometric criteria for the diagnosis of COPD, with 72% agreement (16% of patients clinically diagnosed with COPD did not fulfill the spirometric criteria, while 12% of patients with spirometric criteria of COPD were not considered as having COPD according to clinical criteria).
DISCUSSION
The two differential diagnosis questionnaires also showed moderate concordance between them, with an agreement of 70%. However, the concordance was low between clinical criteria and questionnaires, and very low between spirometry and questionnaires (60% and 61% of agreement with Tinkelman et al and Beeh et al questionnaire respectively). This study assessed the usefulness of the two questionnaires as complementary method of diagnosis; in fact, neither questionnaire was designed as a diagnostic methods but rather to facilitate the differentiation of asthma and COPD once a chronic obstructive airway disease had been diagnosed. 11, 17 In their study, Beeh and colleagues 17 concluded that, by means of their questionnaire, most patients with a suspected or established diagnosis of obstructive airway diseases could be classified in asthmatic or COPD groups. Despite the slight improvement achieved with the addition of spirometry results, these authors recognised that spirometry should be mandatory to support the initial diagnosis of an obstructive airway disease and to guide therapy. On the other hand, Tinkelman and colleagues 11 found their questionnaire to be useful for patients suspected of having obstructive lung disease or those receiving respiratory medications in the absence of a specific diagnosis, although they did recognise the importance of a more efficient use of spirometry and a enhanced diagnostic accuracy to improve the overall management. On observing the poor concordance shown in the current study it was concluded that the questionnaires are of little help in addition to clinical assessment and spirometry with bronchodilator test for the differential diagnosis between asthma and COPD.
Considering the four methods together, the concordance was only of 26%, a percentage probably corresponding to patients with a 'pure phenotype'. These results confirm that a significant number of patients with asthma and COPD may share symptoms that may lead to a misdiagnosis between the two conditions. It is known that the overlap of symptoms can complicate a clear distinction between these two diseases, especially in smokers and in older adults. 11 Age and smoking history are factors that could contribute to the misdiagnosis of COPD in people with asthma.
Although asthma is most often associated with childhood and adolescence, the first manifestation of asthma may also occur in late adulthood. 25 On the other hand, although smoke exposure is closely related to COPD, up to 30% of people with asthma are smokers. 22 Accordingly, the present study found that the mean age at onset was 46.5 and 34 years of age in patients classified as COPD or asthma respectively. In addition, 87.5% of active or ex-smokers were classified as COPD while only 42.6% were diagnosed with asthma. These data fit well with the results from a similar study that showed percentages of 85.4% and 41.7% respectively. 15 This lack of concordance illustrates the difficulty of finding a method to achieve a reliable diagnosis, and shows that a high percentage of patients may not present a pure symptomatic frame. In this context, Gibson and Simpson 22 have defined the overlap syndrome of asthma and COPD as symptoms of increased variability of airflow and incompletely reversible airflow obstruction. Overlap between asthma and COPD can reach 20% of all patients with chronic respiratory disease. 17, 26 British Journal of General Practice, February 2012 e73 but only first-line treatment in patients with severe COPD with frequent exacerbations, and always associated with a long-acting bronchodilator. 3, 6, 7 Assuming that the use of ICs may be excessive or inappropriate in COPD, one aim of the study was to ascertain the adequacy of prescription of these agents. The study found that a high percentage of patients clinically diagnosed with COPD were treated with ICs, both in association with LABAs (47.1%) or alone (24.3%). Similarly, a high number of patients classified as 'indeterminate' were treated with ICs (40.6% in association with LABAs and 15.6% alone). Previous studies have also found ICs among the drugs most frequently used in COPD in primary care, being between 50% and 75% of patients according to the different surveys.
8,27-32 De Miguel Díez et al 32 found a similar percentage of prescriptions in primary care and by pneumologists (64% and 60.9% respectively).
The use of combined therapy could be justified in the case of indeterminate patients, in whom this treatment covers the two processes. However, the authors have no explanation for the use of ICs alone in COPD. On the other hand, the current study showed a considerable number of patients with asthma not receiving ICs (12%). On analysing the use of ICs taking into account the concordance between the four methods evaluated, it was found that when all coincided in the diagnosis of COPD the percentage of patients on treatment with ICs was of 40% (in association with LABAs) and 5% (alone). In contrast, when the four diagnoses were 'non-COPD', the use of ICs with or without LABAs was of 42 and 15% respectively. This means that ICs may be over-used in the case of COPD and underused when the diagnosis is non-COPD.
In conclusion, in many cases it may be difficult to reach a proper diagnosis of chronic respiratory diseases such as COPD and asthma. The overlapping of symptoms, the lack of a gold standard, and the existence of confounding factors, such as the degree of reversibility in airflow, older age, and smoking habits, contribute to misdiagnosis of these conditions. With the combined use of four methods this study found a substantial non-concordance in the diagnosis in patients attending primary care. From a clinical point of view, the differential diagnosis between the two diseases is important, as the therapeutic approach is different. Apart from patients with a non-accurate diagnosis, this study also detected inadequate use of ICs even in patients correctly diagnosed. This suggests that, in spite of the number of guidelines available for the diagnosis and treatment of respiratory diseases, these are not sufficiently implemented in the primary care setting.
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